{
    "medicine_id": "2180eded6bc6cbb81c5bee85c0062603ff6e4c86",
    "platform_id": "DB09108",
    "metadata": {
        "name": "Nuwiq 4000 iU 2 5mL Kit",
        "composition": "4000 iU 2 5mL Simoctocog alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A congenital factor VIII deficiency FDA Label",
            "contraindications": {
                "disease": "Simoctocog alfa is not expected to cause any adverse effects on the human reproductive functions or the human fetus As genotoxicity studies and carcinogenicity studies are not applicable for recombinant products such studies were not performed According to the single dose toxicity study in rats there were no deaths or notable life threatening changes to the treatment and the highest non lethal intravenous dose was determined to be 10 000 IU kg L1115 In a repeated dose toxicity study in monkeys there was no evidence of systemic toxicity There were no observable local reactions at the injection sites based on the findings of a rabbit local tolerance study L1115 Although the formation of neutralizing antibodies inhibitors to FVIII is a specified warning precaution of simoctocog alfa treatment there have been no cases of inhibitior development throughout clinical studies L1115 No cases of overdose have been reported with simoctocog alfa L1115",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Simoctocog alfa is an antihemorrhagic agent that displays comparable hemostatic efficacy as the endogenous coagulation factor VIII Following administration of simoctocog alfa an increase plasma levels of factor VIII is observed to temporarily correct factor VIII deficiency and bleeding tendencies L1115",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}